Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited
diseases through diagnostic tests as well as clinical and research
services, today announced that it has filed an application for listing
its common shares on The NASDAQ Capital Market.

The Company's proposed listing on The NASDAQ Capital Market is subject
to review by NASDAQ and dependent upon the Company meeting all relevant
quantitative and qualitative listing criteria of NASDAQ. The Company
believes it currently meets all of NASDAQ's eligibility requirements
with the exception of the minimum bid price requirement, which will be
addressed by a reverse split of the Company's common stock.

In addition to the NASDAQ Capital Market application, Transgenomic also
announced that its Board of Directors has approved a 1-for-12 reverse
split of its issued and outstanding shares of common stock, with a
planned effective date of January 27, 2014. After giving effect to the
reverse stock split, every 12 shares of the Company's issued and
outstanding common stock will automatically be combined into one share
of the Company's issued and outstanding common stock. The common stock
will trade for 20 business days under the temporary ticker symbol
"TBIOD," with the "D" added to signify that the reverse split has
occurred. After 20 business days, the symbol will revert back to the
original symbol.

After the reverse split, the number of shares outstanding will be
reduced from approximately 88.3 million shares to approximately 7.4
million shares. In connection with the reverse split, stockholders will
not receive fractional post-reverse stock split shares; instead, holders
will receive cash in lieu of fractional shares. The reverse stock split
will not modify the rights or preferences of the common stock.

"This reverse stock split, combined with a possible uplisting to The
NASDAQ Capital Market, is the ext important step for Transgenomic in
becoming a strong molecular diagnostics company," said Paul Kinnon,
President and Chief Executive Officer of Transgenomic. "If approved, an
uplisting to NASDAQ, the world's largest and most recognized electronic
trading market, is expected to benefit both our business operations and
stockholders through increased awareness and visibility within the
investment community, improved share liquidity, and greater access to
capital."

Stockholders who hold their shares in brokerage accounts or "street
name" will not be required to take any action to effect the exchange of
their shares following the reverse split. Holders of share certificates
will receive instructions from the Company's transfer agent, Wells Fargo (News - Alert)
Bank Minnesota, N.A., regarding the process for exchanging their shares.
Wells Fargo Bank Minnesota, N.A. can be reached at (800) 468-9716.

Although the Company believes its common stock will be accepted for
listing on NASDAQ, it cannot provide assurances that NASDAQ will
ultimately approve the Company's application for listing on The NASDAQ
Capital Market.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com)
is a global biotechnology company advancing personalized medicine in
cardiology, oncology, and inherited diseases. The Company has three
complementary business units: Patient Testing, Biomarker Identification,
and Genetic Assays and Platforms, which provide specialized diagnostic
tests, contract research services for drug development, and equipment,
reagents and other consumables for clinical and research applications in
molecular testing and cytogenetics.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. Forward-looking
statements include, but are not limited to, those with respect to the
proposed uplisting of the Company's common stock to The Nasdaq Capital
Market, including the potential benefits of the uplisting, the Company's
ability to meet the quantitative and qualitative listing criteria of
NASDAQ and the potential impact of the Company's reverse stock split.
The known risks, uncertainties and other factors affecting these
forward-looking statements include the risk that the reverse stock split
does not have the anticipated impact, the risk that the Company does not
meet or maintain the quantitative and qualitative listing criteria of
NASDAQ, the risk that the Company's application to list its common stock
on NASDAQ is not approved and the other risks described from time to
time in Transgenomic's filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ materially
from those referred to in such statements. Accordingly, the Company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with
respect to all statements contained in this press release. All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.